Back to Search
Start Over
Venetoclax: Bcl-2 inhibition for the treatment of chronic lymphocytic leukemia.
Venetoclax: Bcl-2 inhibition for the treatment of chronic lymphocytic leukemia.
- Source :
-
Drugs of today (Barcelona, Spain : 1998) [Drugs Today (Barc)] 2016 Apr; Vol. 52 (4), pp. 249-60. - Publication Year :
- 2016
-
Abstract
- Venetoclax (ABT-199) is a small-molecule selective oral inhibitor of the antiapoptotic protein Bcl-2 that promotes programmed cell death of chronic lymphocytic leukemia (CLL) cells regulating the release of proapoptotic factors, such as Smac/Diablo, apoptosis-inducing factor (AIF) and cytochrome c. In April 2016, the U.S. Food and Drug Administration (FDA) granted accelerated approval to venetoclax for patients diagnosed with CLL with 17p deletion, as detected by an FDA-approved test, who have received at least one prior therapy. This review will focus on the mechanism of action, preclinical studies and clinical development of venetoclax both as a monotherapy and in combination with other drugs for CLL in the current milieu of therapy dominated by novel tyrosine kinase inhibitors such as ibrutinib and idelalisib.<br /> (Copyright 2016 Prous Science, S.A.U. or its licensors. All rights reserved.)
- Subjects :
- Antineoplastic Combined Chemotherapy Protocols therapeutic use
Bridged Bicyclo Compounds, Heterocyclic administration & dosage
Bridged Bicyclo Compounds, Heterocyclic pharmacology
Humans
Sulfonamides administration & dosage
Sulfonamides pharmacology
Antineoplastic Agents therapeutic use
Bridged Bicyclo Compounds, Heterocyclic therapeutic use
Leukemia, Lymphocytic, Chronic, B-Cell drug therapy
Proto-Oncogene Proteins c-bcl-2 antagonists & inhibitors
Sulfonamides therapeutic use
Subjects
Details
- Language :
- English
- ISSN :
- 1699-3993
- Volume :
- 52
- Issue :
- 4
- Database :
- MEDLINE
- Journal :
- Drugs of today (Barcelona, Spain : 1998)
- Publication Type :
- Academic Journal
- Accession number :
- 27252989
- Full Text :
- https://doi.org/10.1358/dot.2016.52.4.2470954